1,665.50
-10.50
(-0.63%)
Real-time:
12:12pm BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 1,664.00 - 1,695.00 |
| 52 week | 1,314.00 - 1,816.00 |
| Open | 1,685.50 |
| Vol / Avg. | 1.82M/5.97M |
| Mkt cap | 81,964.75M* |
| P/E | 19.71 |
| Div/yield | 18.00/4.50* |
| EPS | 0.85* |
| Shares | 4,921.33M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jun 12, 2013
GlaxoSmithKline Pharmaceuticals Ltd at Goldman Sachs Healthcare Conference
Jun 3, 2013
Morphosys AG Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 Conference Call
May 29, 2013
GlaxoSmithKline at Deutsche Bank dbAccess Health Care Conference
May 21, 2013
GlaxoSmithKline American Thoracic Society Conference Call
Apr 24, 2013
Q1 2013 GlaxoSmithKline PLC Earnings Conference Call
Apr 23, 2013
GlaxoSmithKline at Biotechnology Industry Organization (BIO) International Convention
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 15.90% | 17.95% |
| Operating margin | 24.42% | 27.97% |
| EBITD margin | - | 35.78% |
| Return on average assets | 9.78% | 11.49% |
| Return on average equity | 61.70% | 65.96% |
| Employees | 98,681 | - |
| Carbon Disclosure Rating | - | 90/100 |
Address
C8 Gsk House, 980 Great West Road
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG.
Officers and directors
| Andrew Philip Witty | Chief Executive Officer, Executive Director | |
| Simon Dingemans | Chief Financial Officer, Executive Director | |
| Moncef Slaoui | Chairman - Research & Development, Executive Director | |
| Deirdre P. Connelly | President - North American Pharmaceuticals | |
| Roger Connor | President - Global Manufacturing & Supply | |
| Marc Dunoyer | Chairman - GSK Japan, Global Head - GSK Rare Diseases | |
| Shah Abbas Hussain | President - Europe & EMAP | |
| Patrick Vallance | President - Pharmaceuticals R&D | |
| Emma Walmsley | President - Consumer Healthcare Worldwide | |
| Christophe Weber | President - Vaccines |
